VWF and thrombotic thrombocytopenic purpura: TAGX-0004 as a new generation of anti-vWF aptamer also had a superior affinity to the vWF A1 domain and could inhibit platelet aggregation ex vivo, potentially could be developed as an appealing agent not only for the treatment of acute Thrombotic Thrombocytopenic Purpura but also arterial thrombotic disorders (Matsumoto and Harada, 2022).